Printer Friendly

Quantel Medical Receives FDA Approval to Market Non-Ablative Aramis Medical Laser for the Treatment of Acne.

CLERMONT-FERRAND, France, Dec. 2 /PRNewswire/ -- Quantel Medical, an international market leader in ultrasound and laser systems for Ophthalmology and Dermatology announced today that it has received the Food and Drug Administrations (FDA) approval to market the non-ablative Aramis Er:Glass 1.54 nm Dermatology Laser for its use to treat acne on the back. Already approved by the FDA for general dermatological use including dermal remodeling and wrinkle reduction, the additional approval to market the Aramis laser for the treatment of acne will provide patients with a new non-ablative treatment option, with a shorter treatment cycle and no side effects as an alternative to powerful drugs, antibiotics, topical creams and lotions.

Acne is a disease of the sebaceous gland of the skin and is caused by clogged pores by the increased sebum production and the presence of bacteria. This leads to a thickening or inflammation of the lining of the follicle, resulting in less severe acne known as blackheads and whiteheads to inflammatory papules and pustules, or to the most severe acne known as nodules and cysts which can lead to scarring.

With more than 40% of teenagers and a significant percentage of the adult population afflicted, acne is one of the most challenging conditions facing physicians today. On average, American Dermatologists see 10-20 acne patients per day. Other than Accutane and its numerous, often severe side effects that include dry skin, birth defects and severe depression, a few of the options available to physicians were to keep the infection under control, either using oral and topical antibiotics, topical medication or blue light irradiation. Oral antibiotics (erythromycin, minocyclin and tetracycline) may take several months to clear up acne, can cause upset stomach, diarrhea, loss of appetite, nausea, can reduce effectiveness of birth control and must be taken daily to be effective or acne will return. Topical antibiotics are limited in their ability to penetrate the skin and clear more deep seated acne and also need to be taken for several months. Topical medication or creams are also limited in their ability to penetrate the skin and cost Americans on average over $100 million per year. Blue light therapy requires several treatments. In all cases, only the symptoms were treated, not the cause. Using the Aramis, a non-invasive laser is a huge discovery in the treatment of acne that's been a long time coming for physicians needing a new treatment option.

Clinical studies both in Europe and the U.S. conclude that the Aramis Laser treats the source of acne by altering the sebaceous gland. It reduces sebum production and sterilizes the target, clearing acne and minimizing its recurrence. Each individual treatment results in an approximate 25% improvement with optimal results after just four treatments -- each at two- week intervals. Patient satisfaction is high with no evidence of side effects, edema, erythema and no pain. Patients also noticed an overall improvement in the appearance of the skin.

Quantel Medical, the manufacturer of the Aramis Laser is an industry leader worldwide. The company's luminaries have received International Dermatological awards for their peer reviewed published clinical study papers.

The Aramis Laser is currently available in North America by Med-Surge Technologies, exclusive distributor for Quantel Medical. In North America please visit http://www.medsurgetech.com/ , or call 800-787-4417. In rest of world please visit http://www.quantel-medical.fr/ , or call +33 (0)4 73 745 745.
 Contacts: International North America
 Christine Warren Beth Emmert
 Quantel Medical Med-Surge Technologies
 +33 (0)4 73 745 745 (972) 720-0425, ext. 223



CONTACT: International, Christine Warren of Quantel Medical, +33-0-4-73-745-745; or North America, Beth Emmert of Med-Surge Technologies, +1-972-720-0425, ext. 223

Web site: http://www.medsurgetech.com/ http://www.quantel-medical.fr/
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 2003
Words:613
Previous Article:'Columbia Remembered' Texas License Plate Available; New Plate Funds Aviation and Space Activities, Columbia Crew Memorial Scholarships.
Next Article:TruLogica Announces System Integrator Partnership With Project Performance Corporation; Partnership Extends TruLogica's Identity Management...
Topics:


Related Articles
ICN Pharmaceuticals Expands Dermatology Business With Acquisition of Non-Ablative Laser Technology.
ICN Pharmaceuticals to Launch New U.S. Growth Platform For Side-Effect-Free Laser Wrinkle Removal Therapy.
New NLITE(TM) Laser Collagen Replenishment (LCR) System Study Data to Be Presented at Upcoming American Society for Laser Medicine & Surgery (ASLMS)...
FDA Clears ICN's NLite(TM) Aesthetic Laser System For Treatment of Wrinkles in General.
Quantel Medical Launches Worldwide Clinical Study to Validate Aramis Medical Laser for the Treatment of Acne.
FDA Approval of Restylane Creates a Filler-Frenzy; Top Cosmetic Surgeon, Dr. Simon Ourian, Is Among the First to Treat Patients With This Natural...
Med-Surge Technologies Announces U.S. Introduction of the MeDioStar(R) HC-Pro High-Power Diode Laser for Hair Removal at The American Academy of...
Acne Patients Seeing the Light: New Laser Therapy Prevents Acne From Graduating to Scars.
Cynosure's TriStar(TM) Laser Selected by New York's Juva(R) Skin & Laser Center and Medispa(R).
Cynosure and DUSA Pharmaceuticals to Collaborate in Phase II Clinical Trial.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters